Two-Step Covalent Docking with Attracting Cavities

被引:6
作者
Goullieux, Mathilde [1 ]
Zoete, Vincent [1 ,2 ]
Rohrig, Ute F. [1 ]
机构
[1] SIB Swiss Inst Bioinformat, Mol Modeling Grp, CH-1015 Lausanne, Switzerland
[2] Lausanne Univ, UNIL CHUV, Dept Oncol, CH-1066 Epalinges, Switzerland
基金
瑞士国家科学基金会;
关键词
PROTEIN-LIGAND DOCKING; DRUG DISCOVERY; STRUCTURE PREDICTION; FORCE-FIELD; INHIBITORS; BINDING; VALIDATION; RESISTANCE; DESIGN; DYNAMICS;
D O I
10.1021/acs.jcim.3c01055
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Due to their various advantages, interest in the development of covalent drugs has been renewed in the past few years. It is therefore important to accurately describe and predict their interactions with biological targets by computer-aided drug design tools such as docking algorithms. Here, we report a covalent docking procedure for our in-house docking code Attracting Cavities (AC), which mimics the two-step mechanism of covalent ligand binding. Ligand binding to the protein cavity is driven by nonbonded interactions, followed by the formation of a covalent bond between the ligand and the protein through a chemical reaction. To test the performance of this method, we developed a diverse, high-quality, openly accessible re-docking benchmark set of 95 covalent complexes bound by 8 chemical reactions to 5 different reactive amino acids. Combination with structures from previous studies resulted in a set of 304 complexes, on which AC obtained a success rate (rmsd <= 2 & Aring;) of 78%, outperforming two state-of-the-art covalent docking codes, genetic optimization for ligand docking (GOLD (66%)) and AutoDock (AD (35%)). Using a more stringent success criterion (rmsd <= 1.5 & Aring;), AC reached a success rate of 71 vs 55% for GOLD and 26% for AD. We additionally assessed the cross-docking performance of AC on a set of 76 covalent complexes of the SARS-CoV-2 main protease. On this challenging test set of mainly small and highly solvent-exposed ligands, AC yielded success rates of 58 and 28% for re-docking and cross-docking, respectively, compared to 45 and 17% for GOLD.
引用
收藏
页码:7847 / 7859
页数:13
相关论文
共 85 条
[31]   Ph4Dock: Pharmacophore-based protein-ligand docking [J].
Goto, J ;
Kataoka, R ;
Hirayama, N .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (27) :6804-6811
[32]   SwissDock, a protein-small molecule docking web service based on EADock DSS [J].
Grosdidier, Aurelien ;
Zoete, Vincent ;
Michielin, Olivier .
NUCLEIC ACIDS RESEARCH, 2011, 39 :W270-W277
[33]   CovBinderInPDB: A Structure-Based Covalent Binder Database [J].
Guo, Xiao-Kang ;
Zhang, Yingkai .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2022, 62 (23) :6057-6068
[34]   FACTS:: Fast analytical continuum treatment of solvation [J].
Haberthuer, Urs ;
Caflisch, Amedeo .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 2008, 29 (05) :701-715
[35]  
Halford B, 2020, CHEM ENG NEWS, V98, P28, DOI 10.1021/cen-09843-cover
[36]  
Halgren TA, 1996, J COMPUT CHEM, V17, P553, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<553::AID-JCC3>3.0.CO
[37]  
2-T
[38]   Diverse, high-quality test set for the validation of protein-ligand docking performance [J].
Hartshorn, Michael J. ;
Verdonk, Marcel L. ;
Chessari, Gianni ;
Brewerton, Suzanne C. ;
Mooij, Wijnand T. M. ;
Mortenson, Paul N. ;
Murray, Christopher W. .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (04) :726-741
[39]   Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 [J].
Herman, Sarah E. M. ;
Gordon, Amber L. ;
Hertlein, Erin ;
Ramanunni, Asha ;
Zhang, Xiaoli ;
Jaglowski, Samantha ;
Flynn, Joseph ;
Jones, Jeffrey ;
Blum, Kristie A. ;
Buggy, Joseph J. ;
Hamdy, Ahmed ;
Johnson, Amy J. ;
Byrd, John C. .
BLOOD, 2011, 117 (23) :6287-6296
[40]   Covalent Warheads Targeting Cysteine Residue: The Promising Approach in Drug Development [J].
Huang, Fangjiao ;
Han, Xiaoli ;
Xiao, Xiaohui ;
Zhou, Jinming .
MOLECULES, 2022, 27 (22)